Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740356 | 0.82 | KDM4E (0.39) | BCHEACHE | |
| SCHEMBL2332858 | 0.71 | BCHE (0.46) | BCHEACHE | |
| SCHEMBL2335924 | 0.67 | PRKCA (0.55) | ACHE | |
| Iodide SCHEMBL2331356 | 0.66 | BCHE (0.52) | BCHEACHE | |
| SCHEMBL2336825 | 0.65 | ACHE (0.37) | BCHEACHE | |
| SCHEMBL14738733 | 0.64 | CHKA (0.40) | ACHE | |
| SCHEMBL14739219 | 0.64 | CHKA (0.40) | ACHE | |
| SCHEMBL2329328 | 0.64 | CHKA (0.40) | ACHE | |
| SCHEMBL14740376 | 0.61 | CHKA (0.41) | ACHE | |
| SCHEMBL13979479 | 0.61 | ACHE (0.46) | BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196652-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2015-07-16 | — | — | US | disclosed |
| US-9024005-B2 | Nucleic acid complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2015-05-05 | — | — | US | disclosed |
| US-20140274800-A1 | TRANSCRIPTION FACTOR DECOYS FOR THE TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY BACTERIA INCLUDING CLOSTRIDIUM DIFFICILE | PROCARTA BIOSYSTEMS LTD. (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20130252881-A1 | Transcription Factor Decoys | PROCARTA BIOSYSTEMS LTD. (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130059775-A1 | Nucleic Acid Complexes | PROCARTA BIOSYSTEMS LTD (GB) | 2013-03-07 | — | — | US | disclosed |
| EP-2533815-A1 | NUCLEIC ACID COMPLEXES | Procarta Biosystems Ltd (GB) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098829-A1 | NUCLEIC ACID COMPLEXES | PROCARTA BIOSYSTEMS LTD (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150196652-A1 | NUCLEIC ACID COMPLEXES | ZFR, SUB1, RELA | BCHE 4569/4885ACHE 4834/4885 |
| US-20130059775-A1 | Nucleic Acid Complexes | ZFR, SUB1, RELA | BCHE 4569/4885ACHE 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.